GYRE - MCAP CO - Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc. (GYRE) is developing biopharmaceutical projects to combat liver pathologies, demonstrating high macro-resilience regardless of economic cycles. This chart reflects a current share price of 0.78, confirming the issuer's market position. Stable sales revenue in Asia allows the company to fund global fibrosis research, outpacing competitors in the speed of bringing innovations to the global market.

The strong scientific reputation of Gyre Therapeutics, Inc. (GYRE) in the therapy of fibrotic organ diseases forms the fundamental basis for asset valuation. An analysis of the company's weighted market capitalization, representing the product of the current share price and the total volume of issuance, allows for a comparison of the market consensus with the actual scale of the business, determining the current cost of capital and the sustainability of the growth trend.